局部治疗对转移性激素敏感性前列腺癌局部事件抑制作用的系统综述与Meta分析
该系统综述与Meta分析纳入6项研究(含2项随机对照试验),评估在全身治疗基础上加用局部治疗(根治性前列腺切除术或放疗)对转移性激素敏感性前列腺癌患者局部事件的预防效果。结果显示局部治疗联合全身治疗组总体局部事件发生率显著低于单纯全身治疗组(RR 0.50,95%CI 0.28-0.88,p=0.016)。
要点
- 局部治疗联合全身治疗组总体局部事件发生率显著低于单纯全身治疗组(RR 0.50,95%CI 0.28-0.88,p=0.016)。
- 根治性前列腺切除术显著降低总体局部事件(RR 0.24,95%CI 0.11-0.52)及需手术干预的局部事件(RR 0.08,95%CI 0.03-0.25)。
- 放疗联合全身治疗组需手术干预的局部事件显著低于单纯全身治疗组(RR 0.70,95%CI 0.49-0.99)。
核心结论
- 在某些转移性激素敏感性前列腺癌患者中,对原发肿瘤行根治性前列腺切除术或放疗似乎可降低局部进展及需手术干预事件的发生率。
- 作者认为,需识别最可能从局部治疗中获益的患者及治疗时机(如转移灶响应后),以设计评估原发肿瘤治疗风险、获益与替代方案的研究。
研究设计与样本
- 系统综述与Meta分析,检索三个数据库及会议摘要(2023年11月),纳入6项研究,其中2项为随机对照试验。
- 比较局部治疗(根治性前列腺切除术或放疗)联合全身治疗与单纯全身治疗(即未行前列腺放疗或根治性前列腺切除术)的转移性激素敏感性前列腺癌患者。
- 主要结局为预防因局部疾病进展导致的总体局部事件(尿路感染、尿路梗阻和肉眼血尿)。
- 按局部治疗类型(根治性前列腺切除术或放疗)进行亚组分析。
主要发现
- 局部治疗联合全身治疗组总体局部事件发生率显著低于单纯全身治疗组(RR 0.50,95%CI 0.28-0.88,p=0.016)。
- 根治性前列腺切除术显著降低总体局部事件发生率(RR 0.24,95%CI 0.11-0.52)及需手术干预的局部事件发生率(RR 0.08,95%CI 0.03-0.25)。
- 放疗联合全身治疗组与单纯全身治疗组在总体局部事件方面无统计学显著差异,但放疗联合全身治疗组需手术干预的局部事件发生率显著更低(RR 0.70,95%CI 0.49-0.99)。
- 局部治疗组需手术干预的上尿路局部事件显著更低(RR 0.60,95%CI 0.37-0.98,p=0.04)。
- 亚组分析显示,根治性前列腺切除术或放疗均未显著影响需手术干预的上尿路局部事件的预防。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,在某些转移性激素敏感性前列腺癌患者中,对原发肿瘤行根治性前列腺切除术或放疗似乎可降低局部进展及需手术干预事件的发生率。
- 作者指出,需识别最可能从局部治疗中获益的患者及治疗时机(如转移灶响应后),以设计评估原发肿瘤治疗风险、获益与替代方案的研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: It remains unclear to what extent the therapy of the primary local tumor, such as radical prostatectomy (RP) and radiation therapy (RT), improves overall survival in patients with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). However, data suggest a benefit of these therapies in preventing local events secondary to local tumor progression. OBJECTIVE: To evaluate the efficacy of adding local therapy (RP or RT) to systemic therapies, including androgen deprivation therapy, docetaxel, and/or androgen receptor axis-targeted agents, in preventing local events in mHSPC patients compared with systemic therapy alone (ie, without RT of the prostate or RP). EVIDENCE ACQUISITION: Three databases and meeting abstracts were queried in November 2023 for studies analyzing mHSPC patients treated with local therapy. The primary outcome of interest was the prevention of overall local events (urinary tract infection, urinary tract obstruction, and gross hematuria) due to local disease progression. Subgroup analyses were conducted to assess the differential outcomes according to the type of local therapy (RP or RT). EVIDENCE SYNTHESIS: Overall, six studies, comprising two randomized controlled trials, were included for a systematic review and meta-analysis. The overall incidence of local events was significantly lower in the local treatment plus systemic therapy group than in the systemic therapy only groups (relative risk [RR]: 0.50, 95% confidence interval [CI]: 0.28-0.88, p = 0.016). RP significantly reduced the incidence of overall local events (RR: 0.24, 95% CI: 0.11-0.52) and that of local events requiring surgical intervention (RR: 0.08, 95% CI: 0.03-0.25). Although there was no statistically significant difference between the RT plus systemic therapy and systemic therapy only groups in terms of overall local events, the incidence of local events requiring surgical intervention was significantly lower in the RT plus systemic therapy group (RR: 0.70, 95% CI: 0.49-0.99); local events requiring surgical intervention of the upper urinary tract was significantly lower in local treatment groups (RR: 0.60, 95% CI: 0.37-0.98, p = 0.04). However, a subgroup analysis revealed that neither RP nor RT significantly impacted the prevention of local events requiring surgical intervention of the upper urinary tract. CONCLUSIONS: In some patients with mHSPC, RP or RT of primary tumor seems to reduce the incidence of local progression and events requiring surgical intervention. Identifying which patients are most likely to benefit from local therapy, and at what time point (eg, after response of metastases), will be necessary to set up a study assessing the risk, benefits, and alternatives to therapy of the primary tumor in the mHSPC setting. PATIENT SUMMARY: Our study suggests that local therapy of the prostate, such as radical prostatectomy or radiotherapy, in patients with metastatic hormone-sensitive prostate cancer can prevent local events, such as urinary obstruction and gross hematuria.
引用
- Tsuboi I, Matsukawa A, Kardoust Parizi M, et al. A Systematic Review and Meta-analysis of the Impact of Local Therapies on Local Event Suppression in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38575408. doi:10.1016/j.euo.2024.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。